DESLANOSIDE

SynDRA canonical compound SYN0013773 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · OTC
Primary target(s)	ATP1A1 \| ATP1A2 \| ATP1A3 \| ATP1A4 \| ATP1B1 \| ATP1B2 \| ATP1B3 \| FXYD2
Mechanism of action	Na/K-ATPase inhibitor
Indication	cardiac arrythmia \| congestive heart failure
Disease area	cardiology

All known targets

Cedilanid D
Deacetylanatoside C
Deacetyllanatoside C
desace
Desacetyllanatoside C
Deslanatoside C
Deslanoside C
Purpurea glycoside C
Deslanosido
Deacetylanatoside c
Cedilanid-d
Ceglunat
Desace
Deslanosidum
Glucodigoxin
Lekozid
Sediranido
DesacetylLanatoside
Desacetyldigilanide C
Deslanosidum C
Lanatosid C
Cedilanid-D
Desacetyl-Lanatoside C
Deslanosido [INN-Spanish]
Deslanosidum [INN-Latin]
Cedilanid-d (TN)
Deslanoside (JP15/USP/INN)
Deslanoside [USAN:BAN:INN:JAN]
(3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid
3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid
3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
glucodigoxin
YGY317RK75
DTXCID302897
CHEBI:31468
Desacetyl Lanatoside